Archives202520242023202220212020201920182017201620152014201320122011 August 11, 2022Result of Broker Option / PDMR Dealings Read More August 04, 2022INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More August 03, 2022Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More July 07, 2022Initiation of research Read More June 28, 20222022 Result of ANNUAL GENERAL MEETING – all resolutions passed Read More June 27, 2022Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More June 21, 2022Lanstead Capital Investors LP share holding update Read More June 11, 2022FDA confirms response date for Type C Meeting as 29th August 2022 Read More June 01, 2022Notice of AGM & Annual Report & Accounts Read More May 25, 2022FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021 Read More May 04, 2022UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More 123
August 04, 2022INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More
August 03, 2022Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More
June 27, 2022Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More
April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
